Stockreport

Assembly Biosciences Presents Interim Data from Two Phase 2a Studies of ABI-H0731 in HBV-Infected Subjects in a Late-Breaker Oral Session at EASL 2019

Assembly Biosciences, Inc.  (ASMB) 
Last assembly biosciences, inc. earnings: 3/4 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.assemblybio.com/investor-relations
PDF - Favorable safety and tolerability profile- Superior antiviral activity with ABI-H0731 in combination with nucleos(t)ide therapies- Selected for inclusion in “Best of I [Read more]